Xanthic Biopharma Inc.
2100 Bloor St. West, Suite 6339
Toronto, ON M6S 5A5

XANTHIC INVITES CURRENT SHAREHOLDERS AND POTENTIAL INVESTORS TO PARTICIPATE IN A CORPORATE INVESTOR UPDATE CALL

FOR IMMEDIATE RELEASE

Toronto, Ontario – June 4, 2018 - Xanthic Biopharma Inc. (formerly Aurquest Resources Inc.) ("**Xanthic**", CSE: xTHC, the Company) is pleased to invite its current shareholders and potential investors to a Corporate Investor Update call. The call is scheduled to take place on June 6, 2018, at 8:30AM EST. Participants can dial in toll-free at 1-866-332-3747 and use the access code 8364216 to join.

The Corporate Investor Update call will be hosted by Tim Moore (CEO) and David Bhumgara (CFO) and will cover both current initiatives and recent corporate milestones. Callers will be muted until the end of the update, during which a short question period will take place.

About Xanthic

Xanthic, through its wholly-owned operating subsidiary, Xanthic Biopharma Limited, provides valuable intellectual property to cannabis industry participants, enabling its strategic partners to produce high quality, innovative, non-combustible cannabis, and cannabis-infused products which deliver consistent THC and/or CBD levels and improved bioavailability. Using a proprietary process, Xanthic allows its strategic partners to deliver superior cannabinoid solubility, improved bioavailability, accurate micro-dosing and greater consistency versus competitive infused products. Through its investment in Avitas CBD Water, Xanthic has access to non-cannabis derived CBD-infused products that qualify for distribution outside of the cannabis dispensary network and into mainstream retail. www.xanthicbio.com

For further information or questions, contact:

Tim Moore, CEO
Xanthic Biopharma Inc.
timm@xanthicbiopharma.com
Phone: 1-647-966-6536
info@xanthicbiopharma.com

Disclaimer:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. There is no assurance that the Agreement with Avitas will successfully produce benefits for Xanthic. Although such forward-looking statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances, except as required pursuant to applicable securities laws.